Dexamethasone preferentially suppresses plasmacytoid dendritic cell differentiation and enhances their apoptotic death

被引:36
作者
Abe, M
Thomson, AW
机构
[1] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Ctr Med, Thomas E Starzl Transplantat Inst, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Ctr Med, Dept Immunol, Pittsburgh, PA 15213 USA
关键词
plasmacytoid dendritic cells; glucocorticoid; interferon-alpha; Toll-like receptor; apoptosis; differentiation;
D O I
10.1016/j.clim.2005.09.019
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Plasmacytoid dendritic cells (pDC) are an important source of type-1 interferon (IFN) following microbial infection and also play key roles in the induction of innate and adaptive immune responses. Here, we show that the glucocorticoid (GC) dexamethasone (Dex) strikingly reduces pDC (and myeloid DC) numbers in secondary lymphoid tissue and liver of normal and hematopoietic growth factor-mobilized mice and suppresses pDC differentiation from bone marrow precursors in vitro. Moreover, the apoptotic death of pDC in vitro was enhanced by exposure to Dex. Notably, however, Toll-like receptor 9 expression and virally induced IFN alpha production by residual pDC from Dex-treated animals were unaffected. Thus, whereas marked reduction in absolute numbers of pDC by GC may predispose to viral infection, often associated with GC-mediated immuno suppression, reductions in pDC and IFN alpha production may contribute to the beneficial effects on GC observed in systemic autoimmune disease, in which that both pDC and IFN alpha have been implicated. alpha 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:300 / 306
页数:7
相关论文
共 47 条
  • [41] High-dose intravenous glucocorticoid therapy abrogates circulating dendritic cells
    Suda, T
    Chida, K
    Matsuda, H
    Hashizume, H
    Ide, K
    Yokomura, K
    Suzuki, K
    Kuwata, H
    Miwa, S
    Nakano, H
    Fujisawa, T
    Enomoto, N
    Matsushita, A
    Nakamura, H
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 112 (06) : 1237 - 1239
  • [42] Van den Heuvel MM, 1999, CLIN EXP IMMUNOL, V115, P577
  • [43] Vieira PL, 1998, J IMMUNOL, V161, P5245
  • [44] Corticosteroids prevent generation of CD34+-derived dermal dendritic cells but do not inhibit langerhans cell development
    Woltman, AM
    Massacrier, C
    de Fijter, JW
    Caux, C
    van Kooten, C
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (12) : 6181 - 6188
  • [45] Woltman AM, 2000, EUR J IMMUNOL, V30, P1807, DOI 10.1002/1521-4141(200007)30:7<1807::AID-IMMU1807>3.0.CO
  • [46] 2-N
  • [47] Longitudinal alteration of circulating dendritic cell subsets and its correlation with steroid treatment in patients with severe acute respiratory syndrome
    Zhang, Z
    Xu, DP
    Li, YG
    Jin, L
    Shi, M
    Wang, M
    Zhou, XZ
    Wu, H
    Gao, GF
    Wang, FS
    [J]. CLINICAL IMMUNOLOGY, 2005, 116 (03) : 225 - 235